Insmed Inc (INSM)

May 28, 2025, 7:10 AM EDT - 6 days ago

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

May 21, 2025, 4:05 PM EDT - 13 days ago

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

May 8, 2025, 2:55 PM EDT - 26 days ago

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 26 days ago

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 11:30 AM EDT - 5 weeks ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR GKOS ISRG LLY RDNT

Apr 29, 2025, 7:00 AM EDT - 5 weeks ago

Insmed To Present at the BofA Securities 2025 Health Care Conference

Apr 25, 2025, 11:58 AM EDT - 5 weeks ago

Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 24, 2025, 7:00 AM EDT - 5 weeks ago

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Apr 23, 2025, 5:00 PM EDT - 5 weeks ago

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Apr 23, 2025, 7:00 AM EDT - 5 weeks ago

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

Mar 27, 2025, 7:40 AM EDT - 2 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI GPCR MRK SWTX

Mar 25, 2025, 8:00 AM EDT - 2 months ago

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Mar 10, 2025, 8:00 AM EDT - 3 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 25, 2025, 4:19 PM EST - 3 months ago

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says

Feb 24, 2025, 8:00 AM EST - 3 months ago

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Feb 20, 2025, 12:50 PM EST - 3 months ago

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 7:00 AM EST - 3 months ago

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 11, 2025, 8:00 AM EST - 4 months ago

Insmed To Present at March 2025 Investor Conferences

Feb 10, 2025, 8:00 AM EST - 4 months ago

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Feb 7, 2025, 10:30 AM EST - 4 months ago

Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity

Feb 6, 2025, 8:00 AM EST - 4 months ago

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Jan 10, 2025, 8:00 AM EST - 5 months ago

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 8:00 AM EST - 5 months ago

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 6 months ago

Insmed To Present at December 2024 Investor Conferences

Nov 20, 2024, 2:09 PM EST - 6 months ago

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Nov 6, 2024, 8:00 AM EST - 7 months ago

Insmed To Present at November 2024 Investor Conferences

Oct 31, 2024, 2:31 PM EDT - 7 months ago

Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:00 AM EDT - 7 months ago

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

Oct 24, 2024, 4:05 PM EDT - 7 months ago

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Oct 23, 2024, 8:00 AM EDT - 7 months ago

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

Oct 17, 2024, 8:00 AM EDT - 8 months ago

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

Oct 8, 2024, 4:05 PM EDT - 8 months ago

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Aug 28, 2024, 5:31 PM EDT - 9 months ago

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Aug 9, 2024, 4:11 PM EDT - 10 months ago

Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 10 months ago

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

Jul 29, 2024, 8:00 AM EDT - 11 months ago

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024

Jul 3, 2024, 9:03 AM EDT - 11 months ago

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

Jun 11, 2024, 8:44 AM EDT - 1 year ago

Top 4 Health Care Stocks That May Keep You Up At Night This Month

APLT LLY TMDX

Jun 5, 2024, 8:00 AM EDT - 1 year ago

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 4, 2024, 4:38 PM EDT - 1 year ago

Insmed (INSM) CEO on the Company's Current Product Pipeline

May 30, 2024, 4:05 PM EDT - 1 year ago

Insmed to Host Commercial Webinar on June 4, 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

May 28, 2024, 6:40 PM EDT - 1 year ago

Insmed CEO on lung disease treatment and path forward

May 28, 2024, 6:21 PM EDT - 1 year ago

Insmed Announces Proposed $500 Million Public Offering of Common Stock

May 28, 2024, 5:25 PM EDT - 1 year ago

Insmed Stock More Than Doubled in Value Tuesday—Here's Why

May 28, 2024, 1:40 PM EDT - 1 year ago

Chart of the Day: Insmed

May 28, 2024, 12:10 PM EDT - 1 year ago

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

May 28, 2024, 7:08 AM EDT - 1 year ago

Insmed stock doubles on positive ASPEN study results

May 28, 2024, 7:06 AM EDT - 1 year ago

Insmed's stock rockets toward a 2-decade high after positive drug-trial data